A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 25 May 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- 17 May 2018 Planned End Date changed from 31 Mar 2019 to 30 Apr 2020.
- 17 May 2018 Planned primary completion date changed from 31 Mar 2019 to 30 Apr 2020.
- 17 May 2018 Planned initiation date changed from 30 Jun 2017 to 1 Jun 2018.